We sells, distributes and makes three classes of custom tailored products:
- Novel compounds which stimulate selective proliferation of human and other mammalian Natural Killer (NK) cells.
- Monoclonal antibodies directed against cellular markers for cell differentiation and malignant transformation stages.
- Nano and micro scale devices for diagnostics and monitoring of disease/therapy states.
Our R&D activities are devoted to further development of:
- Novel drug molecules which can induce selective proliferation of different subsets of NK cell populations in humans.
- Complementary therapeutic methods for treating cancer and viral/retroviral infections using NK cells as the “cellular magic bullet”
Information and Marketing Strategy
Gimmune GmbH has exclusive license to sell and distributes:
- Novel compounds which stimulate selective proliferation of human and other mammalian Natural Killer (NK) cells. These products and methods are protected by 5 international patents.
- Monoclonal antibodies directed against different tumor and/or cell differentiation markers (carcino-embryonal antigens).